MAPK7 and cancer: To further test this hypothesis, we assessed the effect of pharmacological inhibition of ERK5 (XMD8-92) (Yang et al, 2010) and CDK5 (Seliciclib) (Cicenas et al, 2015) in a panel of NSCLC cancer cells (A549, A427 and H460) bearing mutKRAS.